Sars-cov-2 vaccines
US-2024408193-A1 · Dec 12, 2024 · US
Emulsion vaccine compositions comprising antigen and adjuvant in the aqueous phase
US9545439B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9545439-B2 |
| Application number | US-201514618628-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 10, 2015 |
| Priority date | Jun 20, 2007 |
| Publication date | Jan 17, 2017 |
| Grant date | Jan 17, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Emulsion vaccine formulations containing an antigen and an adjuvant in the aqueous phase are used for the vaccination of animals wherein the adjuvant is an acrylic polymer and/or dimethyl dioctadecyl ammonium bromide (DDA). These formulations can be prepared by mixing an aqueous phase containing the antigen and adjuvant with an oil phase in the presence of an emulsifier.
First claim
Opening claim text (preview).
What is claimed is: 1. A vaccine composition comprising an antigen component and an adjuvant component, wherein the adjuvant component comprises an oil-in-water emulsion, wherein further an aqueous phase of said oil-in-water emulsion comprises dimethyl dioctadecyl ammonium bromide (DDA) and an alkyl-polyacrylic acid (alkyl-PAA). 2. The vaccine composition of claim 1 , wherein said oil comprises at least one oil selected from the group consisting of a mineral oil, a terpene oil, soybean oil, olive oil, and a propylene glycol derivative. 3. The vaccine composition of claim 1 , wherein the adjuvant component further comprises at least one of CpG DNA, lipopolysaccharides, and monophosphoryl lipid A. 4. The vaccine composition of claim 3 , wherein the adjuvant component comprises CpG DNA and monophosphoryl lipid A. 5. The vaccine composition of claim 1 , wherein the composition further comprises one or more emulsifiers. 6. The vaccine composition of claim 1 , wherein the antigen is a poultry vaccine antigen.
Assignees
Inventors
Classifications
for influenza or rhinoviruses · CPC title
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title
Immunostimulants · CPC title
- A61K39/12Primary
Viral antigens · CPC title
Emulsions, e.g. Freund's adjuvant, MF59 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9545439B2 cover?
- Emulsion vaccine formulations containing an antigen and an adjuvant in the aqueous phase are used for the vaccination of animals wherein the adjuvant is an acrylic polymer and/or dimethyl dioctadecyl ammonium bromide (DDA). These formulations can be prepared by mixing an aqueous phase containing the antigen and adjuvant with an oil phase in the presence of an emulsifier.
- Who is the assignee on this patent?
- Zoetis Services Llc
- What technology area does this patent fall under?
- Primary CPC classification A61K39/12. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).